Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory T-Cell Hematologic Malignancies

NCT06909474 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT06909474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06909474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory T-Cell Hematologic Malignancies
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2025
Completion date
March 31, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-all/lymphoma